cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.14872800
title: Analyzing the clinical benefit of newer therapies for advanced or metastatic non-small-cell lung cancer: application of the ESMO-magnitude of clinical benefit scale v1.1

description: Despite newer therapies, advanced or metastatic non-small-cell lung cancer (NSCLC) continues to be the leading cause of cancer-related deaths worldwide. Deficits in the design and methods of randomized controlled trials (RCTs) may contribute to reducing the clinical benefit of therapies in oncology. To prioritize treatments based on efficacy results and toxicity data, the <i>European Society for Medical Oncology</i> (ESMO) has developed the Magnitude of Clinical Benefit Scale (MCBS). The objective of this study was to apply the ESMO-MCBS v1.1 to a cohort of RCTs on therapies for advanced or metastatic NSCLC. Phase III and pivotal phase II trials, published between 2013 and 2018, investigating drug therapies for advanced NSCLC were included. <i>PubMed</i> was specifically searched for efficacy/toxicity updates. Treatments were graded 5 to 1 on the ESMO-MCBS v1.1, using the lower limit of the 95% confidence interval of the hazard ratio (HR), where scores 5 and 4 represent a substantial clinical benefit. Additionally, scores using the point estimate HR were generated, for comparison. Discrepancies between our grade estimations and the ones published on the ESMO website, as scorecards, were identified. ESMO-MCBS scores were calculated for 42 positive clinical trials. 54.8% met the ESMO-MCBS thresholds for clinically meaningful benefit (final grade of 4 or 5). That percentage decreased to 40.5% when considering the point estimate of the HR. 50.0% of the trials had no published scorecard on the ESMO website and discrepancies affected 11 (26.2%) studies. Almost half of the RCTs showing a statistically significant result favoring the experimental arm, failed to demonstrate a substantial clinical benefit according to the ESMO framework.
DOI: 10.6084/m9.figshare.14872800.v1
title: Analyzing the clinical benefit of newer therapies for advanced or metastatic non-small-cell lung cancer: application of the ESMO-magnitude of clinical benefit scale v1.1

description: Despite newer therapies, advanced or metastatic non-small-cell lung cancer (NSCLC) continues to be the leading cause of cancer-related deaths worldwide. Deficits in the design and methods of randomized controlled trials (RCTs) may contribute to reducing the clinical benefit of therapies in oncology. To prioritize treatments based on efficacy results and toxicity data, the <i>European Society for Medical Oncology</i> (ESMO) has developed the Magnitude of Clinical Benefit Scale (MCBS). The objective of this study was to apply the ESMO-MCBS v1.1 to a cohort of RCTs on therapies for advanced or metastatic NSCLC. Phase III and pivotal phase II trials, published between 2013 and 2018, investigating drug therapies for advanced NSCLC were included. <i>PubMed</i> was specifically searched for efficacy/toxicity updates. Treatments were graded 5 to 1 on the ESMO-MCBS v1.1, using the lower limit of the 95% confidence interval of the hazard ratio (HR), where scores 5 and 4 represent a substantial clinical benefit. Additionally, scores using the point estimate HR were generated, for comparison. Discrepancies between our grade estimations and the ones published on the ESMO website, as scorecards, were identified. ESMO-MCBS scores were calculated for 42 positive clinical trials. 54.8% met the ESMO-MCBS thresholds for clinically meaningful benefit (final grade of 4 or 5). That percentage decreased to 40.5% when considering the point estimate of the HR. 50.0% of the trials had no published scorecard on the ESMO website and discrepancies affected 11 (26.2%) studies. Almost half of the RCTs showing a statistically significant result favoring the experimental arm, failed to demonstrate a substantial clinical benefit according to the ESMO framework.
DOI: 10.6084/m9.figshare.14607588
title: Outcome and safety analysis of endometrial cancer patients treated with postoperative 3D-conformal radiotherapy or intensity modulated radiotherapy

description: We sought to analyze the toxicity rates and the treatment outcomes in endometrial cancer (EC) patients treated with postoperative three-dimensional conformal radiotherapy (3DCRT) and intensity-modulated radiotherapy (IMRT). The clinical data of 646 EC patients treated with postoperative adjuvant 3DCRT (265 patients, 41%) or with IMRT (381 patients, 59%) between April 2007 and August 2019 were retrospectively analyzed. The primary endpoints were treatment-related acute and late gastrointestinal (GI) and genitourinary (GU) toxicities. The secondary endpoints were LC and overall survival (OS) and disease-free survival (DFS). Median follow-up time was 37 months. The rates for acute GI and GU toxicities of any grade for the entire group were 55.6% and 46.8%, respectively. Acute grade ≥2 GI toxicity was significantly less in patients treated with IMRT compared to those treated with 3DCRT (11.0% vs. 19.2%, <i>p</i>=.004). However, no significant difference grade ≥2 GU toxicities was observed between the 3DCRT and IMRT groups (15.1% vs. 11.0%; <i>p</i>=.15). Acute grade ≥2 GI and GU toxicities were higher in patients receiving systemic chemotherapy, while paraaortic field irradiation increases only the risk of acute grade ≥2 GI toxicity. Estimated 3-year late grade ≥3 GI toxicity rates in the 3DCRT- and IMRT-treated patients were 4.6% and 1.9% (<i>p</i>= .03), respectively. The patients treated with adjuvant ChT had higher rates of late serious GI complications than those without adjuvant ChT. No significant difference in terms of survival and disease control was observed between the 3DCRT and IMRT treatment groups. No significant factor for LC was found in the multivariate analysis. In this multicentric study involving one of largest patient population, we found that IMRT-treated EC patients showed comparable clinical outcomes but with a lower incidence of GI toxicities compared with those treated with 3DCRT.
DOI: 10.6084/m9.figshare.14607588.v1
title: Outcome and safety analysis of endometrial cancer patients treated with postoperative 3D-conformal radiotherapy or intensity modulated radiotherapy

description: We sought to analyze the toxicity rates and the treatment outcomes in endometrial cancer (EC) patients treated with postoperative three-dimensional conformal radiotherapy (3DCRT) and intensity-modulated radiotherapy (IMRT). The clinical data of 646 EC patients treated with postoperative adjuvant 3DCRT (265 patients, 41%) or with IMRT (381 patients, 59%) between April 2007 and August 2019 were retrospectively analyzed. The primary endpoints were treatment-related acute and late gastrointestinal (GI) and genitourinary (GU) toxicities. The secondary endpoints were LC and overall survival (OS) and disease-free survival (DFS). Median follow-up time was 37 months. The rates for acute GI and GU toxicities of any grade for the entire group were 55.6% and 46.8%, respectively. Acute grade ≥2 GI toxicity was significantly less in patients treated with IMRT compared to those treated with 3DCRT (11.0% vs. 19.2%, <i>p</i>=.004). However, no significant difference grade ≥2 GU toxicities was observed between the 3DCRT and IMRT groups (15.1% vs. 11.0%; <i>p</i>=.15). Acute grade ≥2 GI and GU toxicities were higher in patients receiving systemic chemotherapy, while paraaortic field irradiation increases only the risk of acute grade ≥2 GI toxicity. Estimated 3-year late grade ≥3 GI toxicity rates in the 3DCRT- and IMRT-treated patients were 4.6% and 1.9% (<i>p</i>= .03), respectively. The patients treated with adjuvant ChT had higher rates of late serious GI complications than those without adjuvant ChT. No significant difference in terms of survival and disease control was observed between the 3DCRT and IMRT treatment groups. No significant factor for LC was found in the multivariate analysis. In this multicentric study involving one of largest patient population, we found that IMRT-treated EC patients showed comparable clinical outcomes but with a lower incidence of GI toxicities compared with those treated with 3DCRT.
DOI: 10.6084/m9.figshare.14825041
title: Combination of aneuploidy and high S-phase fraction indicates increased risk of relapse in stage I endometrioid endometrial carcinoma

description: Endometrioid endometrial carcinoma is a cancer type with generally excellent prognosis when diagnosed at an early stage, but there is a subset of patients with relapsing disease in spite of early diagnosis and surgical treatment. There is a need to find prognostic markers to identify these patients with increased risk of relapse. Depth of myometrial invasion, histological grade, and presence of lymphovascular invasion are known risk factors. DNA content (ploidy) and proliferation measured as S-phase fraction (SPF) have been discussed as prognostic markers but need additional evaluation. We evaluated relapse-free survival (RFS) with respect to ploidy and SPF, which was analyzed by flow cytometry on fresh tumor tissue, in a cohort of 1001 women treated for stage I endometrioid endometrial carcinoma in northern Sweden during the period of 1993–2010, with a median follow up time of 12.0 years. Data were obtained from historical records. In simple analysis, both aneuploidy and high SPF were associated to increased risk of relapse with hazard ratios (HR) 2.37 (95% CI 1.52–3.70) and 1.94 (95% CI 1.24–3.02), respectively. Our data also confirmed stage, tumor grade, and ploidy as independent prognostic markers in an age adjusted cox regression multivariable analysis but we did not find SPF to contribute to prognosis. However, the combination of aneuploidy and high SPF identified a group of patients with increased risk of relapse, HR 2.02 (95% CI 1.19–3.44). In this study, which is the largest study of ploidy and SPF in stage I endometrioid endometrial carcinoma using fresh frozen tissue, aneuploidy was shown to be an independent prognostic marker. Furthermore, the combination of aneuploidy and high SPF could be used to identify patients with increased risk of relapse.
DOI: 10.6084/m9.figshare.14825041.v2
title: Combination of aneuploidy and high S-phase fraction indicates increased risk of relapse in stage I endometrioid endometrial carcinoma

description: Endometrioid endometrial carcinoma is a cancer type with generally excellent prognosis when diagnosed at an early stage, but there is a subset of patients with relapsing disease in spite of early diagnosis and surgical treatment. There is a need to find prognostic markers to identify these patients with increased risk of relapse. Depth of myometrial invasion, histological grade, and presence of lymphovascular invasion are known risk factors. DNA content (ploidy) and proliferation measured as S-phase fraction (SPF) have been discussed as prognostic markers but need additional evaluation. We evaluated relapse-free survival (RFS) with respect to ploidy and SPF, which was analyzed by flow cytometry on fresh tumor tissue, in a cohort of 1001 women treated for stage I endometrioid endometrial carcinoma in northern Sweden during the period of 1993–2010, with a median follow up time of 12.0 years. Data were obtained from historical records. In simple analysis, both aneuploidy and high SPF were associated to increased risk of relapse with hazard ratios (HR) 2.37 (95% CI 1.52–3.70) and 1.94 (95% CI 1.24–3.02), respectively. Our data also confirmed stage, tumor grade, and ploidy as independent prognostic markers in an age adjusted cox regression multivariable analysis but we did not find SPF to contribute to prognosis. However, the combination of aneuploidy and high SPF identified a group of patients with increased risk of relapse, HR 2.02 (95% CI 1.19–3.44). In this study, which is the largest study of ploidy and SPF in stage I endometrioid endometrial carcinoma using fresh frozen tissue, aneuploidy was shown to be an independent prognostic marker. Furthermore, the combination of aneuploidy and high SPF could be used to identify patients with increased risk of relapse.
DOI: 10.6084/m9.figshare.14825041.v1
title: Combination of aneuploidy and high S-phase fraction indicates increased risk of relapse in stage I endometrioid endometrial carcinoma

description: Endometrioid endometrial carcinoma is a cancer type with generally excellent prognosis when diagnosed at an early stage, but there is a subset of patients with relapsing disease in spite of early diagnosis and surgical treatment. There is a need to find prognostic markers to identify these patients with increased risk of relapse. Depth of myometrial invasion, histological grade, and presence of lymphovascular invasion are known risk factors. DNA content (ploidy) and proliferation measured as S-phase fraction (SPF) have been discussed as prognostic markers but need additional evaluation. We evaluated relapse-free survival (RFS) with respect to ploidy and SPF, which was analyzed by flow cytometry on fresh tumor tissue, in a cohort of 1001 women treated for stage I endometrioid endometrial carcinoma in northern Sweden during the period of 1993–2010, with a median follow up time of 12.0 years. Data were obtained from historical records. In simple analysis, both aneuploidy and high SPF were associated to increased risk of relapse with hazard ratios (HR) 2.37 (95% CI 1.52–3.70) and 1.94 (95% CI 1.24–3.02), respectively. Our data also confirmed stage, tumor grade, and ploidy as independent prognostic markers in an age adjusted cox regression multivariable analysis but we did not find SPF to contribute to prognosis. However, the combination of aneuploidy and high SPF identified a group of patients with increased risk of relapse, HR 2.02 (95% CI 1.19–3.44). In this study, which is the largest study of ploidy and SPF in stage I endometrioid endometrial carcinoma using fresh frozen tissue, aneuploidy was shown to be an independent prognostic marker. Furthermore, the combination of aneuploidy and high SPF could be used to identify patients with increased risk of relapse.
DOI: 10.34740/kaggle/dsv/2613557
title: Blood pressure readings
DOI: 10.6084/m9.figshare.16616125
title: Supplementary Material for: Colonization and Development of the Fecal Microflora of South China Tiger Cubs (<b><i>Panthera tigris amoyensis</i></b>) by Sequencing of the 16S rRNA Gene

description: Postnatal colonization and development of the gut microbiota is linked to health and growth. A comprehensive understanding of the postnatal compositional changes and development of the microbial community is helpful to understand the gut health and improve the survival rate of South China tiger cubs (<i>Panthera tigris amoyensis</i>). Fecal samples from three tiger cubs were collected on the day of birth in 2018 (June 17–21 [G0], July 18 [G1], July 31 [G2], and August 7 [G3]). The 16S rRNA genes of the fecal microflora were sequenced. Results showed that 38 phyla, 58 classes, 134 orders, 272 families, and 636 genera of bacteria from 3,059 operational taxonomic units were identified from 12 fecal samples. The diversity and abundance of species of group G0 were significantly higher (<i>p</i> &lt; 0.05 or 0.01) than those of groups G2 and G3. The predominant phylum was Proteobacteria in groups G0 and G1 (38.85% and 48%, respectively) and Firmicutes in groups G2 and G3 (71.42% and 75.29%, respectively). At the phylum level, the abundance of Deinococcus-Thermus was significantly decreased in groups G1, G2, and G3 as compared to group G0 (<i>p</i> &lt; 0.05), while that of Firmicutes was significantly increased in groups G2 and G3 (<i>p</i> &lt; 0.05). At the genus level, the abundance of <i>Faecalibacterium</i>, <i>Ralstonia</i>, and unidentified <i>Rickettsiales</i> was significantly decreased in groups G1, G2, and G3 as compared with group G0 (<i>p</i> &lt; 0.05), while that of <i>Pseudomonas</i> was significantly decreased in groups G2 and G3 (<i>p</i> &lt; 0.05). The composition and structure of fecal microbiota of South China tiger cubs changed after birth.
DOI: 10.6084/m9.figshare.16616125.v1
title: Supplementary Material for: Colonization and Development of the Fecal Microflora of South China Tiger Cubs (<b><i>Panthera tigris amoyensis</i></b>) by Sequencing of the 16S rRNA Gene

description: Postnatal colonization and development of the gut microbiota is linked to health and growth. A comprehensive understanding of the postnatal compositional changes and development of the microbial community is helpful to understand the gut health and improve the survival rate of South China tiger cubs (<i>Panthera tigris amoyensis</i>). Fecal samples from three tiger cubs were collected on the day of birth in 2018 (June 17–21 [G0], July 18 [G1], July 31 [G2], and August 7 [G3]). The 16S rRNA genes of the fecal microflora were sequenced. Results showed that 38 phyla, 58 classes, 134 orders, 272 families, and 636 genera of bacteria from 3,059 operational taxonomic units were identified from 12 fecal samples. The diversity and abundance of species of group G0 were significantly higher (<i>p</i> &lt; 0.05 or 0.01) than those of groups G2 and G3. The predominant phylum was Proteobacteria in groups G0 and G1 (38.85% and 48%, respectively) and Firmicutes in groups G2 and G3 (71.42% and 75.29%, respectively). At the phylum level, the abundance of Deinococcus-Thermus was significantly decreased in groups G1, G2, and G3 as compared to group G0 (<i>p</i> &lt; 0.05), while that of Firmicutes was significantly increased in groups G2 and G3 (<i>p</i> &lt; 0.05). At the genus level, the abundance of <i>Faecalibacterium</i>, <i>Ralstonia</i>, and unidentified <i>Rickettsiales</i> was significantly decreased in groups G1, G2, and G3 as compared with group G0 (<i>p</i> &lt; 0.05), while that of <i>Pseudomonas</i> was significantly decreased in groups G2 and G3 (<i>p</i> &lt; 0.05). The composition and structure of fecal microbiota of South China tiger cubs changed after birth.
DOI: 10.5281/zenodo.3715054
title: RT-PCR Verdelli et al.

description: Output RT-PCR
DOI: 10.5281/zenodo.3715053
title: RT-PCR Verdelli et al.

description: Output RT-PCR
DOI: 10.5281/zenodo.5506654
title: Iron phthalocyanine on Au(111) is a "non-Landau" Fermi liquid

description: Datasets (figure source, model definitions) for the manuscript "Iron phthalocyanine on Au(111) is a “non-Landau” Fermi liquid".
DOI: 10.5281/zenodo.4888965
title: Iron phthalocyanine on Au(111) is a "non-Landau" Fermi liquid

description: Datasets (figure source, model definitions) for the manuscript "Iron phthalocyanine on Au(111) is a “non-Landau” Fermi liquid".
DOI: 10.5517/ccdc.csd.cc24x1mr
title: CCDC 1993164: Experimental Crystal Structure Determination

description: Related Article: David T.J. Morris, Steven M. Wales, David P. Tilly, Elliot H.E. Farrar, Matthew N. Grayson, John W. Ward, Jonathan Clayden|2021|Cell Press: Chem|7|2460|doi:10.1016/j.chempr.2021.06.022
DOI: 10.5517/ccdc.csd.cc25ysnl
title: CCDC 2024630: Experimental Crystal Structure Determination

description: Related Article: Tun Wu, Zhiyuan Jiang, Qixia Bai, Yiming Li, Shuhua Mao, Hao Yu, Lukasz Wojtas, Zhengbin Tang, Mingzhao Chen, Zhe Zhang, Ting-Zheng Xie, Ming Wang, Xiaopeng Li, Pingshan Wang|2021|Cell Press: Chem|7|2429|doi:10.1016/j.chempr.2021.06.003
DOI: 10.5281/zenodo.4533836
title: Circulating IL-17A Levels in Postmenopausal Women with Primary Hyperparathyroidism

description: Raw data Circulating IL-17A Levels in Postmenopausal Women with Primary Hyperparathyroidism
DOI: 10.5281/zenodo.4533835
title: Circulating IL-17A Levels in Postmenopausal Women with Primary Hyperparathyroidism

description: Raw data Circulating IL-17A Levels in Postmenopausal Women with Primary Hyperparathyroidism
DOI: 10.5517/ccdc.csd.cc282gnh
title: CCDC 2087746: Experimental Crystal Structure Determination

description: Related Article: Zixiao Qin|2021|CSD Communication|||
DOI: 10.5281/zenodo.4533938
title: Hypertryptasemia and Mast Cell-Related Disorders in Severe Osteoporotic Patients.

description: Raw data Hypertryptasemia and Mast Cell-Related Disorders in Severe Osteoporotic Patients.
DOI: 10.5281/zenodo.4533937
title: Hypertryptasemia and Mast Cell-Related Disorders in Severe Osteoporotic Patients.

description: Raw data Hypertryptasemia and Mast Cell-Related Disorders in Severe Osteoporotic Patients.
DOI: 10.5281/zenodo.5506650
title: Field investigations of salt partitioning and aqueous chemistry of freezing closed-basin lakes in Mongolia as terrestrial analogs of subsurface brine reservoirs on icy bodies [Data set]

description: All measurement and calculation data Measurement and calculation data in Version 2 were uploaded in 2021-09-14
DOI: 10.5281/zenodo.4558652
title: Circulating carboxylated osteocalcin correlates with skeletal muscle mass and risk of fall in postmenopausal osteoporotic women

description: <em>Background </em>Bone and skeletal muscle represent a single functional unit. We cross-sectionally investigated body composition, risk of fall and circulating osteocalcin (OC) isoforms in osteoporotic postmenopausal women to test the hypothesis of an involvement of OC in the bone-muscle crosstalk. <em>Materials and methods </em>Twenty-nine non-diabetic, non-obese, postmenopausal osteoporotic women (age 72.4±6.8 years; BMI 23.0±3.3 kg/m2) underwent to: 1) fasting blood sampling for biochemical and hormone assays, including carboxylated (cOC) and uncarboxylated (uOC) osteocalcin; 2) whole-body dual energy X-ray absorptiometry (DXA) to assess total and regional body composition; 3) magnetic resonance imaging to determine cross-sectional muscle area (CSA) and intermuscular adipose tissue (IMAT) of thigh muscles; 4) risk of fall assessment through the OAK system. <em>Results </em>Appendicular skeletal muscle index (ASMMI) was low in 45% of patients. Forty percent got a low OAK score, consistent with moderate-severe risk of fall, which was predicted by low legs lean mass and increased total fat mass. Circulating cOC levels showed significantly correlated with CTx-I, lean mass parameters including IMAT, and OAK score. Fractured and unfractured women did not differ for any of the analyzed parameters, though cOC and uOC positively correlated with legs lean mass, OAK score and bone markers only in fractured women. <em>Conclusions </em>Data supported the relationship between OC and skeletal muscle mass and function in postmenopausal osteoporotic women. Serum cOC, but not uOC, emerges as mediator in the bone- muscle crosstalk. Circulating cOC and uOC levels may be differentially regulated in fractured and unfractured osteoporotic women, suggesting underlying differences in bone metabolism.